Tumor-infiltrating lymphocytes can be activated in situ by using in vivo activants plus F(ab')2 bispecific antibodies

International Journal of Cancer

Volumn 67, Issue 2, 1996, Pages 232-237

  Thibault, Claude ^a   Nelson, Heidi ^a   Chapoval, Andrei I ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GALACTOSAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY SPECIFICITY; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DOSE RESPONSE; IN VIVO STUDY; LETHALITY; LYMPHOCYTE ACTIVATION; MELANOMA CELL; MOLECULAR RECOGNITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; T LYMPHOCYTE ACTIVATION; TUMOR ASSOCIATED LEUKOCYTE;

ANIMALS; ANTIBODIES, BISPECIFIC; CRICETINAE; CYTOTOXICITY, IMMUNOLOGIC; ENTEROTOXINS; GLUCANS; IMMUNOGLOBULIN FAB FRAGMENTS; LYMPHOCYTE ACTIVATION; LYMPHOCYTES, TUMOR-INFILTRATING; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C3H; NEOPLASM TRANSPLANTATION; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0029809014     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19960717)67:2<232::AID-IJC14>3.3.CO;2-1     Document Type: Article

References (20)

1. AOKI, T., Lentinan. In: R. Feniche (ed.), Immune modulation agents and their mechanisms, pp. 63-75, Dekker, New York (1985).
2. CANEVARI, S. and 9 OTHERS, Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T lymphocytes retargeted by a bispecific monoclonal antibody. J. nat. Cancer Inst., 87, 1463-1469 (1995).
3. 2 bifunctional antibody activates and retargets tumor-infiltrating lymphocytes. J Immunol., 155, 1296-1303 (1995).
4. + tumor-specific T-cell clones derived from human melanoma-infiltrating lymphocytes in response to autologous tumor cells in vitro. Europ. J. Immunol., 24, 1966-1973 (1994).
5. HOFFMAN, O.A., OLSON, E.J. and LIMPER, A.H., Fungal beta-glucans modulate macrophage release of tumor necrosis factor-alpha in response to bacterial lipopolysaccharide. Immunol. Lett., 37, 19-25 (1993).
6. HOLMES, E.C., Immunology of tumor infiltrating lymphocytes. Ann. Surg., 201, 158-163 (1985).
7. MIESCHER, S., WHITESIDE, T.L., CARREL, S. and VON FLIEDNER, V., Functional properties of tumor-infiltrating and blood lymphocytes in patients with solid tumors: effects of tumor cells and their supernatants on proliferative responses of lymphocytes. J. Immunol., 136, 1899-1907 (1986).
8. MIETHKE, T., WAHL, C., HEEG, K., ECHTENACHER, B., KRAMMER, P.H. and WAGNER, H., T-cell-mediated lethal shock triggered in mice by the superantigen staphylococcal enterotoxin B: critical role of tumor necrosis factor. J. exp. Med., 175, 91-98 (1992).
9. NELSON, H., RAMSEY, P.S., KERR, L.A., MCKEAN, D.J. and DONOHUE, J.H., Regional and systemic distribution of anti-tumor × anti-CD3 heteroaggregate antibodies and cultured human peripheral blood lymphocytes in a human colon cancer xenograft. J. Immunol., 145, 3507-3515 (1990).
10. OCHI, A., MIGITA, K., XU, J. and SIMINOVITCH, K., In vivo tumor immunotherapy by a bacterial superantigen. J. Immunol., 151, 3180-3186 (1993).
11. PENNA, C., DEAN, P.A. and NELSON, H., Anlitumor × anti-CD3 bifunctional antibodies redirect T-cells activated in vivo with staphylococcal enterotoxin B to neutralize pulmonary metastases. Cancer Res., 54, 2738-2743 (1994).
12. PENNA, C., DEAN, P.A. and NELSON, H., Pulmonary metastases, neutralization and tumor rejection by in vivo administration of β-glucan and bispecific antibody. Int. J. Cancer, 65, 377-382 (1996).
13. REID, J., LUNDY, J., MONSON, J., NELSON, H., RAMSEY, P., ILSTRUP, D. and DONOHUE, J., Heteroconjugated antibodies enhance lymphocyte-mediated tumour cell lysis in vitro and in vivo. Brit. J. Surg., 79, 628-632 (1992).
14. ROSENBERG, S.A., SPIESS, P. and LAFRENIERE, R., A new approach to the adoptive immunotherapy of cancer with tumor infiltrating lymphocytes. Science (Wash.), 233, 1318-1321 (1986).
15. ROSS, G.D. and VETVICKA, V., CR3 (CD11b, CD18): a phagocyte and NK cell membrane receptor with multiple ligand specificities and functions. [Review]. Clin. exp. Immunol., 92, 181-184 (1993).
16. SUZUKI, I., TANAKA, H., KINOSHITA, A., OIKAWA, S., OSAWA, M. and YADOMAE, T., Effect of orally administered beta-glucan on macrophage function in mice. Int. J. Immunopharmacol., 12, 675-684 (1990).
17. TOPALIAN, S.L. and ROSENBERG, S.A., Therapy of cancer using the adoptive transfer of activated killer cells and interleukin-2. Acta haematol., 78 Suppl. 1, 75-76 (1987).
18. TSOUKAS, C.D., LANDGRAF, B., BENTIN, J., VALENTINE, M., LOTZ, M., VAUGHAN, J.H. and CARSON, D.A., Activation of resting T lymphocytes by anti-CD3 (T3) antibodies in the absence of monocytes. J. Immunol., 135, 1719-1723 (1985).
19. 2 fragments -retention of the immunosuppressive properties of whole antibody with marked reduction in T-cell activation and lymphokine release. Trans. plantation, 52, 354-360 (1991).
20. YANG, S.C., FRY, K.D., GRIMM, E.A. and ROTH, J.A., Phenotype and cytolytic activity of mouse tumor-bearer splenocytes and tumorinfiltrating lymphocytes from K-1735 melanoma metastases following anti-CD3, interleukin-2, and tumor necrosis factor-alpha combination immunotherapy. J. Immunother., 10, 326-335 (1991).